Organon Deal History & Licensing Activity
Organon is a mid-size pharma headquartered in US. Over the past three years, Organon has been involved in 7 licensing and acquisition transactions, with a primary focus on Small Molecules (5 deals). The company currently has 6 active clinical trials, primarily in Women's Health.
Deals (12mo)
1
Active Trials
6
Top Modality
Small Molecules
Focus Area
Women's Health
Organon Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Organon in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Organon (company acquisition) | Sun Pharmaceuticals | Other | Approved | acquisition | Apr 2026 |
Organon Pipeline Focus
Therapeutic areas and modalities where Organon is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Organon Strategic Signals
Key indicators of Organon's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Strategic Priorities
Organon Clinical Pipeline
Organon has 6 active clinical trials across 4 development phases.
1
Phase 4
1
Unknown
2
Phase 2
2
Phase 3
See How Your Asset Matches Organon's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Women's Health assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Women's Health Deal Benchmarks
Market sizing, deal terms, and competitive landscape for women's health
Dermatology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for dermatology
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
About Organon Licensing & Deal Activity
Organon is a mid-size pharma company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 7 deals over the past three years, Organon ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Organon include Women's Health (3 deals and trials), Dermatology (3 deals and trials), Solid Tumors (3 deals and trials), and Mega Deals (2 deals and trials). In terms of modality, Organon has shown particular interest in small molecules, other, mab.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Organon and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Organon's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.